Figure 4.
Figure 4. Hematide produced dose-dependent changes in pharmacodynamic parameters. Increase in transferrin soluble receptor (A) and decreases in ferritin (B), content of reticulocyte Hgb (C), and EPO (D). Each panel shows the change from baseline for each parameter over 28 days following Hematide dosing; baseline values were measured immediately prior to Hematide dosing. The symbols in each panel correspond to Hematide doses as follows: ▵, placebo; □, 0.025 mg/kg; ▴ 0.05 mg/kg; ▪, 0.1 mg/kg.

Hematide produced dose-dependent changes in pharmacodynamic parameters. Increase in transferrin soluble receptor (A) and decreases in ferritin (B), content of reticulocyte Hgb (C), and EPO (D). Each panel shows the change from baseline for each parameter over 28 days following Hematide dosing; baseline values were measured immediately prior to Hematide dosing. The symbols in each panel correspond to Hematide doses as follows: ▵, placebo; □, 0.025 mg/kg; ▴ 0.05 mg/kg; ▪, 0.1 mg/kg.

Close Modal

or Create an Account

Close Modal
Close Modal